GlassScriptPhysician profile
Karol Leanne Davis
NPI 1679531891
$1,817.99
in general payments reported to CMS, 2019-2025
24 companies · $468 in 2025
The $468 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $166 · 2020: $50.72 · 2023: $544 · 2024: $589 · 2025: $468.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,601.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,601.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $334.22 | 2023-2025 | Qulipta |
| Astellas Pharma US INC | $262.80 | 2023-2025 | Veozah |
| Lilly USA, LLC | $196.60 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $151.12 | 2019-2024 | Rybelsus, Ozempic, Wegovy |
| Organon LLC | $134.44 | 2023 | Nexplanon |
| Amgen INC. | $108.29 | 2019-2025 | Otezla, Repatha, Evenity |
| Astrazeneca Pharmaceuticals LP | $71.05 | 2023-2024 | Farxiga, Airsupra, Breztri |
| Abbott Laboratories | $67.33 | 2024-2025 | Freestyle Libre 3 |
| Merck Sharp & Dohme LLC | $59.44 | 2023-2025 | Vaxneuvance, Capvaxive, Gardasil 9 |
| Sanofi-Aventis U.S. LLC | $50.75 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $40.34 | 2020-2024 | Jardiance, Tradjenta, Synjardy |
| Glaxosmithkline, LLC. | $37.08 | 2023 | Trelegy Ellipta, Arexvy, Shingrix |
| Boston Scientific Corporation | $34.29 | 2024 | Wavewriter Alpha Prime 16, Watchman Flx |
| Novartis Pharmaceuticals Corporation | $32.65 | 2019-2025 | |
| Hologic Sales and Service, LLC | $31.06 | 2024-2025 | Thinprep 2000 Processor, Aptima |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $29.65 | 2024 | |
| Pfizer INC. | $29.31 | 2023 | |
| Averitas Pharma INC. | $26.87 | 2023 | Qutenza |
| Cequr Corporation | $26.02 | 2023 | Cequr Simplicity |
| Janssen Pharmaceuticals, INC | $22.76 | 2019 | |
| Recor Medical INC | $21.78 | 2025 | Paradise Ultrasound Renal Denervation System |
| E.R. Squibb & Sons, L.L.C. | $19.08 | 2023 | Eliquis |
| Cranial Technologies, INC | $17.07 | 2019 | |
| Exact Sciences Corporation | $13.99 | 2023 | Cologuard Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karol Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.